{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:54:58Z","timestamp":1785354898356,"version":"3.55.0"},"reference-count":56,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Huntington\u2019s disease (HD) is a highly common inherited monogenic neurodegenerative disease, and the gene responsible for its development is located in the 4p16.3 chromosome. The product of that gene mutation is an abnormal huntingtin (Htt) protein that disrupts the neural conduction, thus leading to motor and cognitive disorders. The disease progresses to irreversible changes in the central nervous system (CNS). Although only a few drugs are available to symptomatic treatment, \u2018dopamine stabilizers\u2019 (as represented by the pridopidine) may be the new treatment options. The underlying causes of HD are dopaminergic conduction disorders. Initially, the disease is hyperkinetic (chorea) until it eventually reaches the hypokinetic phase. Studies confirmed a correlation between the amount of dopamine in the CNS and the stage of the disease. Pridopidine has the capacity to be a dopamine buffer, which could increase or decrease the dopamine content depending on the disease phase. A research carried out on animal models demonstrated the protective effect of pridopidine on nerve cells thanks to its ability to alter the cortical glutamatergic signaling through the N-methyl-D-aspartate (NMDA) receptors. Studies on dopamine stabilizers also reported that pridopidine has a 100-fold greater affinity for the sigma-1 receptor than for the D2 receptor. Disturbances in the activity of sigma-1 receptors occur in neurodegenerative diseases, including HD. Their interaction with pridopidine results in the neuroprotective effect, which is manifested as an increase in the plasticity of synaptic neurons and prevention of their atrophy within the striatum. To determine the effectiveness of pridopidine in the treatment of HD, large multicenter randomized studies such as HART, MermaiHD, and PRIDE-HD were carried out.<\/jats:p>","DOI":"10.1515\/revneuro-2019-0085","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T09:01:15Z","timestamp":1581670875000},"page":"441-451","source":"Crossref","is-referenced-by-count":12,"title":["Pridopidine in the treatment of Huntington\u2019s disease"],"prefix":"10.1515","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-8134","authenticated-orcid":false,"given":"Magdalena","family":"Jab\u0142o\u0144ska","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz , Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Grzelakowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz , Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej","family":"Wi\u015bniewski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz , Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Mazur","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz , Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Leis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum in Bydgoszcz , Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Ga\u0142\u0105zka","sequence":"additional","affiliation":[{"name":"Department of General and Oncological Pediatric Surgery , Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University , 85-090 Bydgoszcz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2022062616291805460_j_revneuro-2019-0085_ref_001_w2aab3b7c19b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Bading, H. (2017). Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations. J. Exp. Med. 214, 569\u2013578.","DOI":"10.1084\/jem.20161673"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_002_w2aab3b7c19b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill, R.I., Wetzel, R., et al. (2015). Huntington disease. Nat. Rev. Dis. Prim. 1, 15005.","DOI":"10.1038\/nrdp.2015.5"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_003_w2aab3b7c19b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Cepeda, C., Murphy, K.P., Parent, M., and Levine, M.S. (2014). The role of dopamine in Huntington\u2019s disease. Prog. Brain Res. 211, 235\u2013254.","DOI":"10.1016\/B978-0-444-63425-2.00010-6"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_004_w2aab3b7c19b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Chu, U.B., and Ruoho, A.E. (2016). Biochemical pharmacology of the sigma-1 receptor. Mol. Pharmacol. 89, 142\u2013153.","DOI":"10.1124\/mol.115.101170"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_005_w2aab3b7c19b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Coppen, E.M. and Roos, R.A.C. (2017). Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs 77, 29\u201346.","DOI":"10.1007\/s40265-016-0670-4"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_006_w2aab3b7c19b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Dayalu, P. and Albin, R.L. (2015). Huntington disease: pathogenesis and treatment. Neurol. Clin. 33, 101\u2013114.","DOI":"10.1016\/j.ncl.2014.09.003"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_007_w2aab3b7c19b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"De Yebenes, J.G., Landwehrmeyer, B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R.A., Saft, C., Magnet, M.K., Sword, A., Rembratt, \u00c5., et al. (2011). Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 10, 1049\u20131057.","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_008_w2aab3b7c19b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Dickey, A.S. and La Spada, A.R. (2018). Therapy development in Huntington disease: from current strategies to emerging opportunities. Am. J. Med. Genet. A 176, 842\u2013861.","DOI":"10.1002\/ajmg.a.38494"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_009_w2aab3b7c19b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Dyhring, T., Nielsen, E., Sonesson, C., Pettersson, F., Karlsson, J., Svensson, P., Christophersen, P., and Waters, N. (2010). The dopaminergic stabilizers pridopidine (ACR16) and (\u2212)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur. J. Pharmacol. 628, 19\u201326.","DOI":"10.1016\/j.ejphar.2009.11.025"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_010_w2aab3b7c19b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Francardo, V., Bez, F., Francardo, V., Bez, F., Wieloch, T., Nissbrandt, H., Ruscher, K., and Cenci, M.A. (2014). Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 137, 1998\u20132014.","DOI":"10.1093\/brain\/awu107"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_011_w2aab3b7c19b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Frank, S. (2014). Treatment of Huntington\u2019s disease. Neurotherapeutics 11, 153\u2013160.","DOI":"10.1007\/s13311-013-0244-z"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_012_w2aab3b7c19b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Fujimoto, M., Hayashi, T., Urfer, R., Mita, S., and Su, T.P. (2012). Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse 66, 630\u2013639.","DOI":"10.1002\/syn.21549"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_013_w2aab3b7c19b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Gelderblom, H., W\u00fcstenberg, T., McLean, T., M\u00fctze, L., Fischer, W., Saft, C., Hoffmann, R., S\u00fcssmuth, S., Schlattmann, P., Van Duijn, E., et al. (2017). Bupropion for the treatment of apathy in Huntington\u2019s disease: a multicenter, randomised, double-blind, placebo controlled, prospective crossover trial. PLoS One 12, e0173872.","DOI":"10.1371\/journal.pone.0173872"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_014_w2aab3b7c19b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Geva, M., Kusko, R., Soares, H., Fowler, K.D., Birnberg, T., Barash, S., Merenlender-Wagner, A., Fine, T., Lysaght, A., Weiner, B., et al. (2016). Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum. Mol. Genet. 25, 3975\u20133987.","DOI":"10.1093\/hmg\/ddw238"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_015_w2aab3b7c19b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Ginovart, N., Lundin, A., Farde, L., Halldin, C., B\u00e4ckman, L., Swahn, C.G., Pauli, S., and Sedvall, G. (1997). PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease. Brain 120, 503\u2013514.","DOI":"10.1093\/brain\/120.3.503"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_016_w2aab3b7c19b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Hardingham, G.E. and Bading, H. (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682\u2013696.","DOI":"10.1038\/nrn2911"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_017_w2aab3b7c19b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Harrison, L.M. and LaHoste, G.J. (2013). The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes. Exp. Cell Res. 319, 2310\u20132315.","DOI":"10.1016\/j.yexcr.2013.03.033"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_018_w2aab3b7c19b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Hyrskyluoto, A., Pulli, I., T\u00f6rnqvist, K., Huu Ho, T., Korhonen, L., and Lindholm, D. (2013). Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-\u03baB pathway. Cell Death Dis. 4, e646.","DOI":"10.1038\/cddis.2013.170"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_019_w2aab3b7c19b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Jankovic, J. and Roos, R.A. (2014). Chorea associated with Huntington\u2019s disease: to treat or not to treat? Mov. Disord. 29, 1414\u20131418.","DOI":"10.1002\/mds.25996"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_020_w2aab3b7c19b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Jimenez-Sanchez, M., Licitra, F., Underwood, B.R., and Rubinsztein, D.C. (2017). Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb. Perspect. Med. 7, 1\u201322.","DOI":"10.1101\/cshperspect.a024240"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_021_w2aab3b7c19b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Karl, K., McGarry, A., McDermott, M.P., Kayson, E., Walker, F., Goldstein, J., Hyson, C., Agarwal, P., Deppen, P., Fiedorowicz, J., et al. (2013). A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov. Disord. 28, 1407\u20131415.","DOI":"10.1002\/mds.25362"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_022_w2aab3b7c19b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Kourrich, S., Su, T.P., Fujimoto, M., and Bonci, A. (2012). The sigma-1 receptor: roles in neuronal plasticity and disease. Trends Neurosci. 35, 762\u2013771.","DOI":"10.1016\/j.tins.2012.09.007"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_023_w2aab3b7c19b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Kusko, R., Dreymann, J., Ross, J., Cha, Y., Escalante-Chong, R., Garcia-Miralles, M., Tan, L.J., Burczynski, M.E., Zeskind, B., Laifenfeld, D., et al. (2018). Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol. Neurodegener. 13, 25.","DOI":"10.1186\/s13024-018-0259-3"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_024_w2aab3b7c19b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Lee, J.M., Ramos, E.M., Lee, J.H., Gillis, T., Mysore, J.S., Hayden, M.R., Warby, S.C., Morrison, P., Nance, M., Ross, C.A., et al. (2012). CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78, 690\u2013695.","DOI":"10.1212\/WNL.0b013e318249f683"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_025_w2aab3b7c19b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Malik, M., Rangel-Barajas, C., Sumien, N., Su, C., Singh, M., Chen, Z., Huang, R.Q., Meunier, J., Maurice, T., Mach, R.H., et al. (2015). The effects of sigma (\u03c31) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. Br. J. Pharmacol. 172, 2519\u20132531.","DOI":"10.1111\/bph.13076"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_026_w2aab3b7c19b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Mason, S. and Barker, R. (2016). Novel targets for Huntington\u2019s disease: future prospects. Degener. Neurol. Neuromuscul. Dis. 6, 25\u201336.","DOI":"10.2147\/DNND.S83808"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_027_w2aab3b7c19b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"McColgan, P. and Tabrizi, S.J. (2018). Huntington\u2019s disease: a clinical review. Eur. J. Neurol. 25, 24\u201334.","DOI":"10.1111\/ene.13413"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_029_w2aab3b7c19b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"McGarry, A., Kieburtz, K., Abler, V., Grachev, I.D., Gandhi, S., Auinger, P., Papapetropoulos, S., and Hayden, M. (2017). Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington\u2019s Disease. J. Huntingtons. Dis. 6, 189\u2013199.","DOI":"10.3233\/JHD-170241"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_030_w2aab3b7c19b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"McKinstry, S.U., Karadeniz, Y.B., Worthington, A.K., Hayrapetyan, V.Y., Ilcim Ozlu, M., Serafin-Molina, K., Christopher, R.W., Ustunkaya, T., Dragatsis, I., Zeitlin, S., et al. (2014). Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J. Neurosci. 34, 9455\u20139472.","DOI":"10.1523\/JNEUROSCI.4699-13.2014"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_031_w2aab3b7c19b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Milnerwood, A.J., Kaufman, A.M., Sepers, M.D., Gladding, C.M., Zhang, L., Wang, L., Fan, J., Coquinco, A., Qiao, J.Y., Lee, H., et al. (2012). Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington\u2019s disease mice. Neurobiol. Dis. 48, 40\u201351.","DOI":"10.1016\/j.nbd.2012.05.013"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_032_w2aab3b7c19b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Natesan, S., Svensson, K.A., Reckless, G.E., Nobrega, J.N., Barlow, K.B.L., Johansson, A.M., and Kapur, S. (2006). The dopamine stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine ((-)-OSU6162) and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J. Pharmacol. Exp. Ther. 318, 810\u2013818.","DOI":"10.1124\/jpet.106.102905"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_033_w2aab3b7c19b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Papoutsi, M., Labuschagne, I., Tabrizi, S.J., and Stout, J.C. (2014). The cognitive burden in Huntington\u2019s disease: pathology, phenotype, and mechanisms of compensation. Mov. Disord. 29, 673\u2013683.","DOI":"10.1002\/mds.25864"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_034_w2aab3b7c19b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Ponten, H., Kullingsj\u00f6, J., Lagerkvist, S., Martin, P., Pettersson, F., Sonesson, C., Waters, S., and Waters, N. (2010). In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur. J. Pharmacol. 644, 88\u201395.","DOI":"10.1016\/j.ejphar.2010.07.023"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_035_w2aab3b7c19b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Potkin, K.T. and Potkin, S.G. (2018). New directions in therapeutics for Huntington disease. Future Neurol. 13, 101\u2013121.","DOI":"10.2217\/fnl-2017-0035"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_036_w2aab3b7c19b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Reilmann, R., McGarry, A., Grachev, I.D., Savola, J.M., Borowsky, B., Eyal, E., Gross, N., Langbehn, D., Schubert, R., Wickenberg, A.T., et al. (2019). Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 18, 165\u2013176.","DOI":"10.1016\/S1474-4422(18)30391-0"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_037_w2aab3b7c19b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Ross, C.A. and Tabrizi, S.J. (2011). Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83\u201398.","DOI":"10.1016\/S1474-4422(10)70245-3"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_038_w2aab3b7c19b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Ross, C.A., Aylward, E.H., Wild, E.J., Langbehn, D.R., Long, J.D., Warner, J.H., Scahill, R.I., Leavitt, B.R., Stout, J.C., Paulsen, J.S., et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204\u2013216.","DOI":"10.1038\/nrneurol.2014.24"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_039_w2aab3b7c19b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Ryskamp, D., Wu, J., Geva, M., Kusko, R., Grossman, I., Hayden, M., and Bezprozvanny, I. (2017). The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol. Dis. 97, 46\u201359.","DOI":"10.1016\/j.nbd.2016.10.006"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_040_w2aab3b7c19b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Sahlholm, K., \u00c5rhem, P., Fuxe, K., and Marcellino, D. (2013). The dopamine stabilizers ACR16 and ()-OSU6162 display nanomolar affinities at the \u03c3-1 receptor. Mol. Psychiatry 18, 12\u201314.","DOI":"10.1038\/mp.2012.3"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_041_w2aab3b7c19b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Sahlholm, K., Sijbesma, J.W.A., Maas, B., Kwizera, C., Marcellino, D., Ramakrishnan, N.K., Dierckx, R.A.J.O., Elsinga, P.H., and Van Waarde, A. (2015). Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology (Berl.) 232, 3443\u20133453.","DOI":"10.1007\/s00213-015-3997-8"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_042_w2aab3b7c19b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Sahlholm, K., Valle-Le\u00f3n, M., Fern\u00e1ndez-Due\u00f1as, V., and Ciruela, F. (2018a). Pridopidine reverses phencyclidine-induced memory impairment. Front. Pharmacol. 9, 338.","DOI":"10.3389\/fphar.2018.00338"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_043_w2aab3b7c19b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Sahlholm, K., Valle-Le\u00f3n, M., Taura, J., Fern\u00e1ndez-Due\u0144as, V., and Ciruela, F. (2018b). Effects of the dopamine stabilizer, pridopidine, on basal and phencyclidine-induced locomotion: role of dopamine D2 and sigma-1 receptors. CNS Neurol. Disord. \u2013 Drug Targets 17, 522\u2013527.","DOI":"10.2174\/1871527317666180627103337"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_044_w2aab3b7c19b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Saudou, F. and Humbert, S. (2016). The biology of Huntingtin. Neuron 89, 910\u2013926.","DOI":"10.1016\/j.neuron.2016.02.003"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_045_w2aab3b7c19b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Schmidt, H.R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., and Kruse, A.C. (2016). Crystal structure of the human \u03c31 receptor. Nature 532, 527\u2013530.","DOI":"10.1038\/nature17391"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_046_w2aab3b7c19b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Sciamanna, G., Napolitano, F., Pelosi, B., Bonsi, P., Vitucci, D., Nuzzo, T., Punzo, D., Ghiglieri, V., Ponterio, G., Pasqualetti, M., et al. (2015). Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. Neurobiol. Dis. 78, 146\u2013161.","DOI":"10.1016\/j.nbd.2015.03.021"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_047_w2aab3b7c19b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Snowden, J.S. (2017). The Neuropsychology of Huntington\u2019s Disease. Arch. Clin. Neuropsychol. 32, 876\u2013887.","DOI":"10.1093\/arclin\/acx086"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_048_w2aab3b7c19b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Squitieri, F. and de Yebenes, J.G. (2015). Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Des. Dev. Ther. 9, 5827\u20135833.","DOI":"10.2147\/DDDT.S65738"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_049_w2aab3b7c19b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"Squitieri, F., Di Pardo, A., Favellato, M., Amico, E., Maglione, V., and Frati, L. (2015). Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J. Cell. Mol. Med. 19, 2540\u20132548.","DOI":"10.1111\/jcmm.12604"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_050_w2aab3b7c19b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Tadori, Y., Kitagawa, H., Forbes, R.A., McQuade, R.D., Stark, A., and Kikuchi, T. (2007). Differences in agonist\/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208\u2013912. Eur. J. Pharmacol. 574, 103\u2013111.","DOI":"10.1016\/j.ejphar.2007.07.031"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_051_w2aab3b7c19b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"Tang, B.L. (2018). Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin. Cells 7, 59.","DOI":"10.3390\/cells7060059"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_052_w2aab3b7c19b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Tsai, S.Y., Rothman, R.K., and Su, T.P. (2012). Insights into the sigma-1 receptor chaperone\u2019s cellular functions: a microarray report. Synapse 66, 42\u201351.","DOI":"10.1002\/syn.20984"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_053_w2aab3b7c19b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Van Duijn, E., Kingma, E.M., and Van Der Mast, R.C. (2007). Psychopathology in verified Huntington\u2019s disease gene carriers. J. Neuropsychiatry Clin. Neurosci. 19, 441\u2013448.","DOI":"10.1176\/jnp.2007.19.4.441"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_054_w2aab3b7c19b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Waters, S., Tedroff, J., Ponten, H., Klamer, D., Sonesson, C., and Watersc, N. (2018). Pridopidine: overview of pharmacology and rationale for its use in Huntington\u2019s disease. J. Huntingtons. Dis. 7, 1\u201316.","DOI":"10.3233\/JHD-170267"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_055_w2aab3b7c19b1b6b1ab2b1c54Aa","unstructured":"Weissman, A.D., Su, T.P., Hedreen, J.C., and London, E.D. (1988). Sigma receptors in post-mortem human brains. J. Pharmacol. Exp. Ther. 247, 29\u201333."},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_056_w2aab3b7c19b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"Wexler, A., Wild, E.J., and Tabrizi, S.J. (2016). George Huntington: a legacy of inquiry, empathy and hope. Brain 139, 2326\u20132333.","DOI":"10.1093\/brain\/aww165"},{"key":"2022062616291805460_j_revneuro-2019-0085_ref_057_w2aab3b7c19b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Yapijakis, C. (2017). Huntington disease: genetics, prevention, and therapy approaches. Adv. Exp. Med. Biol. 987, 55\u201365.","DOI":"10.1007\/978-3-319-57379-3_6"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/revneuro\/31\/4\/article-p441.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0085\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T16:35:18Z","timestamp":1656261318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0085\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["10.1515\/revneuro-2019-0085"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2019-0085","relation":{},"ISSN":["2191-0200","0334-1763"],"issn-type":[{"value":"2191-0200","type":"electronic"},{"value":"0334-1763","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}